# 23 — Test Summary Report

## 1. Document Control

| Field | Value |
|---|---|
| Document ID | AE-PY-SUMMARY-001 |
| Project | playwright-python-hybrid-framework |
| Version | 1.0 |
| Status | Complete — pending QA Lead review |
| Prepared By | AI Assistant (advisory, acting as Test Automation Engineer) |
| Date | 2026-08-25 |
| Phase | Phase 17 — Test Summary Report |
| Step | Step 23 — Test Summary Report |
| Predecessor Documents | [01](01-Project-Vision.md)–[22](22-QA-Metrics.md), all ✅ approved |

## 2. Purpose

Evaluate the project's execution cycle against the exit/completion criteria [docs/04-Test-Plan.md](04-Test-Plan.md) itself defined, and consolidate a single known-limitations list from the evidence already produced across [docs/17](17-Execution-Report.md)–[22](22-QA-Metrics.md). Per [docs/05-Test-Strategy.md §22](05-Test-Strategy.md), this document is **one of three inputs to Gate 6** (alongside the defect log and known-limitations list) — it is **not** the Gate 6/Phase 18 release-readiness decision itself, and issues no such decision.

## 3. Scope

Entirely a synthesis of existing, already-approved evidence. No new test was executed, no CI/CD or Docker action was performed, and no source/test/configuration file was touched to produce this document.

## 4. Exit Criteria Evaluation ([docs/04-Test-Plan.md §15](04-Test-Plan.md))

### 4.1 "All test cases planned for the approved automation scope have been executed at least once."

| | |
|---|---|
| **Status** | **NOT MET** |
| **Evidence** | [docs/17-Execution-Report.md §5B/§7](17-Execution-Report.md), [docs/18-Defect-Documentation.md §7](18-Defect-Documentation.md) |
| **Reasoning** | Of the 31 `AUTOMATE`-approved cases, 22 have executed at least once; 9 (`AE-UI-TC-004/005/007/008/021`, `AE-API-TC-007/011/012/014`) have never executed, blocked on account-provisioning authorization that has not been granted at any point in the project. This criterion requires *all* approved cases to have executed — 9 have not, so it is not met. |

### 4.2 "All Critical- and High-priority requirements from docs/03 §13 have either passing evidence or a documented, QA-Lead-accepted exception."

| | |
|---|---|
| **Status** | **NOT MET** |
| **Evidence** | [docs/09-Automation-Scope.md §26](09-Automation-Scope.md): P0 automation = 10/13 = 76.9%; P1 automation = 12/14 = 85.7%. [docs/03-Requirement-Analysis.md §13](03-Requirement-Analysis.md): Critical = 12 requirements, High = 27 requirements. |
| **Reasoning** | Neither the P0 (Critical-adjacent) nor P1 (High-adjacent) automation coverage figure is 100% — 3 P0 items are explicitly excluded (all Checkout E2E cases, [docs/09 §26](09-Automation-Scope.md)), meaning some Critical-priority journeys have no passing evidence and no formally-documented "accepted exception" (as distinct from a still-open, unauthorized blocker — see Section 7). A precise item-by-item cross-check against the full Critical+High list was not performed for this document (see Section 9, Item 3 — a disclosed gap, not silently filled), but the aggregate coverage figures alone are conclusive that the criterion, as stated, is not fully met. |
| **New discrepancy found while preparing this section** | [docs/03-Requirement-Analysis.md §13](03-Requirement-Analysis.md) states `Critical | 12` in its summary table, but its own "Representative Examples" column for that row enumerates 15 distinct identifiers (`REQ-BUS-002/003/004`, `REQ-FUNC-SL-001/003`, `REQ-FUNC-PR-001/002`, `REQ-FUNC-CT-001/004`, `REQ-FUNC-CO-001/004`, `REQ-API-001/007/010`, `REQ-UI-003`), not 12. **Impact:** the true, exact Critical-priority requirement count cannot be confirmed as either 12 or 15 from this table alone, so this report does not assert a precise Critical+High combined total anywhere, and relies only on the already-established P0/P1 automation-coverage percentages (which are computed independently, in [docs/09 §26](09-Automation-Scope.md), not from this count) to reach its NOT MET conclusion. **Not corrected here** — flagged for QA Lead awareness (also carried into Section 9, Item 3). |

### 4.3 "No unresolved Blocker- or Critical-severity defect exists without documented QA Lead acceptance."

| | |
|---|---|
| **Status** | **MET** |
| **Evidence** | [docs/18-Defect-Documentation.md §4-5](18-Defect-Documentation.md) |
| **Reasoning** | Zero confirmed defects exist in any of the four defect categories (Test, Application, Automation, Data). There is no Blocker- or Critical-severity defect to be unresolved. (The one Environment observation, `OBS-001`, is explicitly not a defect — Section 6 — and is already logged as Accepted-Risk.) |

### 4.4 "Regression pass completed for the discovery/cart modules identified as stable in Step 3."

| | |
|---|---|
| **Status** | **MET** |
| **Evidence** | [docs/09-Automation-Scope.md §26](09-Automation-Scope.md) (Discovery/Cart journey automation = 10/10 = 100%); [docs/17 §8](17-Execution-Report.md), [docs/19 §10](19-CI-CD.md), [docs/20 §12](20-Dockerization.md), [docs/21 §7](21-Reporting-Observability.md) (repeated 22/22 clean regression passes, including every Products/Cart case, across 4 independent execution contexts) |
| **Reasoning** | The Discovery/Cart journey has 100% case automation and every regression run from Step 19 onward has produced a clean pass with zero genuine (non-environmental) failures for these modules. |

### 4.5 "Test results, defects, and a Test Summary Report have been reviewed by the QA Lead."

| | |
|---|---|
| **Status** | **PARTIALLY MET / PENDING** |
| **Evidence** | [docs/17](17-Execution-Report.md) and [docs/18](18-Defect-Documentation.md) both carry QA Lead approval (per their own Document Control sections, and the QA Lead's explicit approval messages that advanced each subsequent step). This document (the Test Summary Report itself) is newly produced and has not yet been reviewed. |
| **Reasoning** | Test results and defects: reviewed (approved at Steps 17 and 18 respectively). The Test Summary Report component specifically: cannot be "reviewed" before it exists — it is produced here, and review is the explicit next action requested of the QA Lead (Section 11). |

## 5. Test Completion / Acceptance Evaluation ([docs/04-Test-Plan.md §26](04-Test-Plan.md))

### 5.1 "All test cases in the approved automation scope have executed at least once with recorded results."

Same underlying fact as Section 4.1. **Status: NOT MET.** Same evidence and reasoning — 9 of 31 approved cases have never executed.

### 5.2 "Every Critical/High-priority requirement has verified-passing evidence or a QA-Lead-accepted documented exception."

Same underlying fact as Section 4.2. **Status: NOT MET.** Same evidence and reasoning. Nuance worth stating explicitly: the 9 blocked cases are not *hidden* — they are repeatedly, explicitly documented and have been visible to the QA Lead at every step since [docs/09](09-Automation-Scope.md) — but an open, unauthorized blocker is not the same as a formally "accepted exception." No document anywhere records the QA Lead accepting the current Critical/High coverage gap as a permanent, closed exception; it remains open, pending authorization.

### 5.3 "All identified defects are logged with severity/priority and either resolved, retested, or explicitly accepted as known limitations."

| | |
|---|---|
| **Status** | **MET** |
| **Evidence** | [docs/18-Defect-Documentation.md §4-6](18-Defect-Documentation.md) |
| **Reasoning** | Zero identified defects exist to log/resolve. The one Environment observation (`OBS-001`) is logged, classified, and explicitly recorded with status "Accepted-Risk" — satisfying the "explicitly accepted as a known limitation" clause for the one non-defect finding this project has. |

### 5.4 "A Test Summary Report has been produced and reviewed."

Same underlying fact as Section 4.5. **Status: PARTIALLY MET / PENDING** — produced (this document); review is pending.

### 5.5 "The QA Lead has explicitly signed off that the cycle's evidence is sufficient for its stated portfolio/demonstration purpose."

| | |
|---|---|
| **Status** | **NOT MET / PENDING QA LEAD ACTION** |
| **Evidence** | No document in the project contains this specific sign-off statement. |
| **Reasoning** | This is, by its own wording, an action only the QA Lead can take. This document does not, and cannot, supply that sign-off on the QA Lead's behalf — doing so would overstep this document's role as one input to Gate 6, not the decision itself (Section 2). This criterion remains open until the QA Lead explicitly provides it. |

## 6. Project Scope and Status Summary

| Item | Value | Source |
|---|---|---|
| Total approved Test Cases | 46 | [09 §25](09-Automation-Scope.md) |
| Scope breakdown | 31 `AUTOMATE` / 2 `MANUAL` / 9 `DEFERRED` / 4 `RESTRICTED` | [09 §25](09-Automation-Scope.md) |
| Total collected automated tests (incl. 28 framework/infra) | 50 | [19](19-CI-CD.md)/[20](20-Dockerization.md)/[21](21-Reporting-Observability.md)/[22 §5](22-QA-Metrics.md) |
| Business Test Cases implemented and executed (the "22 executed regression tests") | 22 (12 UI + 9 API + 1 Hybrid) | [17 §5A](17-Execution-Report.md) |
| Disposition breakdown | 22 executed / 9 blocked / 4 restricted / 9 deferred / 2 manual (= 46) | [18 §8](18-Defect-Documentation.md), [22 §6.1](22-QA-Metrics.md) |
| Pass / fail (final confirmed) | 22 passed / 0 failed (non-environmental) | [17 §7](17-Execution-Report.md) |
| Regression selection composition (per-run) | 22 selected / 28 deselected, consistently across Steps 19–21 | [19 §10](19-CI-CD.md), [20 §12](20-Dockerization.md), [21 §7](21-Reporting-Observability.md) |
| Blocked cases and reason | 9 (`AE-UI-TC-004/005/007/008/021`, `AE-API-TC-007/011/012/014`) — unresolved account-provisioning authorization dependency, never granted | [18 §7](18-Defect-Documentation.md) |
| Restricted cases and reason | 4 (`AE-UI-TC-002/003/009/022`) — unrecoverable public side effects on a shared environment | [09 §25](09-Automation-Scope.md) |
| Deferred cases and reason | 9 — unresolved Checkout flow (5), unexplained search anomaly (1), unconfirmed quantity boundary (1), Hybrid cases blocked on UI dependencies (2) | [09 §25](09-Automation-Scope.md) |
| Manual cases and reason | 2 (`AE-UI-TC-010`, `AE-API-TC-013`) — low business value / low incremental value | [09 §25](09-Automation-Scope.md) |
| Defect status | 0 confirmed defects (Test/Application/Automation/Data); 1 Environment observation (`OBS-001`) | [18 §4-6](18-Defect-Documentation.md) |
| Five-way failure classification | Test / Application / Environment / Automation / Data — unchanged, as established | [10 §26](10-Automation-Strategy.md), [18 §2](18-Defect-Documentation.md) |
| `OBS-001` | Environment observation, Accepted-Risk, ~47.6% raw connection-failure rate observed, explicitly not an AUT/Automation defect | [17 §7](17-Execution-Report.md), [18 §6](18-Defect-Documentation.md) |
| Automation coverage (established figures, unchanged) | 31/46 = 67.4% overall; **P0 ceiling 10/13 = 76.9%**; 22/31 = 71.0% implemented-of-approved | [09 §26](09-Automation-Scope.md), [22 §7](22-QA-Metrics.md) |
| Requirement coverage | Step-3 baseline: 24 VERIFIED / 8 PARTIAL / 16 REFERENCE-only of 48; 25 identifiers now have direct execution evidence (narrowing, not replacing, the baseline) | [03 §14](03-Requirement-Analysis.md), [22 §8](22-QA-Metrics.md) |
| API endpoint coverage | 14 total: 9 implemented+passing / 4 blocked / 1 manual | [22 §9](22-QA-Metrics.md) |
| CI/CD status | GitHub Actions, Jenkins, Azure DevOps all implemented and locally/structurally validated; **none has ever been externally executed** | [19 §6a](19-CI-CD.md) |
| Docker status | Implemented, built, and **runtime-validated locally** (real build, 50-test collection, 22/22 pass, report persistence, security inspection) — not pushed to any registry, not wired into any CI platform | [20](20-Dockerization.md) |
| Reporting/observability status | Test Case ID traceability and Execution Platform metadata implemented and locally validated; GitHub Actions/Jenkins/Azure DevOps detection implemented but **not runtime-validated** on those platforms | [21](21-Reporting-Observability.md) |
| Gate 5 | **PARTIAL** | [17 §16](17-Execution-Report.md) |
| Gate 6 | **NOT APPLICABLE** (Release Readiness is Phase 18) | [17 §16](17-Execution-Report.md) |

## 7. External CI Execution — Explicit Status

Per [docs/19-CI-CD.md §6a](19-CI-CD.md), [docs/20-Dockerization.md](20-Dockerization.md), and [docs/21-Reporting-Observability.md §8](21-Reporting-Observability.md): **GitHub Actions, Jenkins, and Azure DevOps execution evidence remains unavailable** — none of the three platforms has ever been externally executed for this project. All CI/CD validation performed to date is local/structural (YAML/Jenkinsfile syntax validation, marker-selection verification, dependency-installation logic checks). This report does not claim otherwise.

**Docker is explicitly distinguished from this**: Docker was **locally runtime-validated** — a real `docker build`, a real in-container `--collect-only` (50 tests), a real default-CMD execution (22/22 passed), and real host report-persistence, all actually performed and recorded ([docs/20 §10-13](20-Dockerization.md)). This is real, local, container-runtime evidence — but it is still **not** the same as external CI-platform execution, and is not conflated with it here.

## 8. Consolidated Known Limitations

Assembled from [docs/17](17-Execution-Report.md)–[22](22-QA-Metrics.md); each restated, not reinterpreted, from its source:

1. **9 approved `AUTOMATE` cases have never executed**, blocked on account-provisioning authorization that has never been granted across the project. ([18 §7](18-Defect-Documentation.md))
2. **The full Critical+High requirement priority list has not been individually cross-checked** against execution evidence in any document, including this one — only aggregate proxy figures (P0/P1 automation coverage) were used (Section 4.2), partly because the exact Critical-priority count itself is ambiguous in its source (Section 9, Item 3).
3. **The full 48-item `REQ-*` requirement-coverage re-classification remains incomplete** — [docs/22 §8.2](22-QA-Metrics.md) narrowed it with 25 execution-evidenced identifiers but explicitly did not rebuild the full traceability matrix ([docs/11 §28](11-Framework-Architecture.md) deferred this originally).
4. **`AE-API-TC-007`/`AE-API-TC-014` carry a still-open SAFE-vs-LIMITED parallelization classification discrepancy** between [docs/09](09-Automation-Scope.md) and [docs/10 §21](10-Automation-Strategy.md) — zero practical effect while both remain blocked/unimplemented, not resolved here (Section 9, Item 1).
5. **`OBS-001`**: a standing, unresolved environmental instability (~47.6% raw connection-failure rate observed) affecting the shared public AUT — outside this project's control, Accepted-Risk, not a defect. ([18 §6](18-Defect-Documentation.md))
6. **A pre-existing, narrower flaky-test finding** (`AE-UI-TC-020`, one occurrence during Step 14 full-suite execution) could not be cleanly distinguished from the later, much larger `OBS-001` signal — an open question, not resolved. ([14 §12](14-UI-Automation.md), [17 §12](17-Execution-Report.md))
7. **No CI/CD platform has ever been externally executed** (Section 7).
8. **Checkout/Order journey automation is only 16.7%** (1/6 relevant cases) — the largest single coverage gap, driven by the same account-authorization blocker (Item 1) plus deferred Checkout-flow verification. ([09 §26](09-Automation-Scope.md))
9. **No release-readiness claim has been made anywhere in the project** — Gate 6 remains NOT APPLICABLE, and Phase 18 has not been reached (Section 10).

## 9. Explicitly Carried-Forward Documentation Gaps

1. **`AE-API-TC-007`/`AE-API-TC-014` SAFE vs. LIMITED classification** — [docs/09-Automation-Scope.md](09-Automation-Scope.md) classifies both SAFE; [docs/10-Automation-Strategy.md §21](10-Automation-Strategy.md) classifies both LIMITED. First disclosed [docs/19 §5](19-CI-CD.md), reaffirmed [docs/20](20-Dockerization.md). **Not resolved by this document.**
2. **Full 48-item `REQ-*` reclassification/traceability gap** from [docs/22 §8.2/§14](22-QA-Metrics.md) — carried forward unchanged, **not resolved by this document.**
3. **Newly found this step**: [docs/03-Requirement-Analysis.md §13](03-Requirement-Analysis.md)'s Critical-priority requirement count (stated as 12) does not match the 15 identifiers enumerated in that same row's "Representative Examples" column (Section 4.2). Source: [docs/03 §13](03-Requirement-Analysis.md). Impact: no document, including this one, can state an exact, confirmed Critical-priority requirement total; this report avoids asserting one and relies on the independently-computed P0 automation-coverage percentage instead. **Not corrected here**, per instruction — reported for QA Lead awareness only.

## 10. Explicit Scope Boundary — This Is Not a Release-Readiness Decision

This document evaluates completion criteria and consolidates known limitations. It does **not**:
- Declare the project "release ready" or "not release ready."
- Issue any Go/No-Go decision.
- Perform or substitute for Phase 18 (Release Readiness), which remains a separate, later, not-yet-reached step.
- Reinterpret Gate 5 (**PARTIAL**, unchanged) or Gate 6 (**NOT APPLICABLE**, unchanged).

Per [docs/05-Test-Strategy.md §22](05-Test-Strategy.md), this report is one of three named inputs to that future Gate 6 decision — a factual record of what happened and what remains outstanding, not the decision itself.

## 11. Recommendation

Two Exit Criteria (§4.3, §4.4) and two Completion criteria (§5.3, and effectively the "defects" portion of others) are fully **MET**. Four criteria across both sections are **NOT MET**, all tracing to the same two root causes: (a) the 9-case account-authorization blocker, and (b) the pending QA Lead review-and-sign-off actions this very document exists to request (§4.5/§5.5). No criterion is unmet due to an application defect, an automation defect, or unaddressed environmental risk — `OBS-001` and the one pre-existing flaky finding are both already logged and accepted, not open problems. The QA Lead's review of this Test Summary Report, and any decision on the authorization blocker, are the two concrete next actions this document identifies — not resolved by it.

## 12. Approval

| Role | Name | Status | Date |
|---|---|---|---|
| Prepared By | AI Assistant (advisory, acting as Test Automation Engineer) | Complete — pending review | 2026-08-25 |
| Reviewed By | QA Lead | Pending | — |
| Approved By | QA Lead | Pending | — |
| Approval Status | **Complete — Pending QA Lead Approval** | | |

Approval of this exit criterion by the QA Lead is required before proceeding to Step 24 / Phase 18. This document does not itself constitute that approval, nor a release-readiness decision.

## 13. Post-Approval Addendum — Step 4–9 Findings (2026-08-27)

**Disclosed, not a silent correction.** Sections 1–12 above remain exactly as originally approved and are not rewritten. §4.3's "9 unexecuted, blocked" reasoning and §11's recommendation were accurate as of this document's original approval and are now superseded by the facts below.

**The 9 previously-blocked cases (§4.3, §Recommendation, [18 §7](18-Defect-Documentation.md)) are now implemented and executed**, via the disposable-account architecture recorded in [18 §14](18-Defect-Documentation.md) (`BLK-001`/`BLK-002` closed there). Evidence: local full-suite execution (`61/61` collected/executed) and real GitHub Actions execution — `Full Project Validation`, run `33037686550`, `60/61 passed, 0 failed, 1 skipped` (the one skip is an unrelated, intentional Tier-1 infrastructure test, not a business case — see [18 §14](18-Defect-Documentation.md)).

**Automation coverage (§9, superseding the "22/31 = 71.0%" figure):** 31/31 `AUTOMATE`-approved cases now implemented and executed at least once, evidence-based, 0 outstanding.

**Gate 5** ([05 §22](05-Test-Strategy.md), "Critical regression complete"): status changes from **PARTIAL** to **MET** — all Critical-priority `REQ-*` items now have passing evidence; no accepted exception remains outstanding for coverage. (`AE-UI-TC-019`'s accepted-risk status, [18 §14](18-Defect-Documentation.md), is a reliability/flakiness classification, not a coverage gap, and does not reopen this gate.)

**§11 Recommendation, updated:** the account-authorization blocker (root cause "a") is resolved. The remaining next action is unchanged in kind: QA Lead review and sign-off ([04 §26](04-Test-Plan.md)) — now against a 31/31-executed evidence base rather than 22/31.
